DE602005026432D1 - Leptin antagonisten - Google Patents

Leptin antagonisten

Info

Publication number
DE602005026432D1
DE602005026432D1 DE602005026432T DE602005026432T DE602005026432D1 DE 602005026432 D1 DE602005026432 D1 DE 602005026432D1 DE 602005026432 T DE602005026432 T DE 602005026432T DE 602005026432 T DE602005026432 T DE 602005026432T DE 602005026432 D1 DE602005026432 D1 DE 602005026432D1
Authority
DE
Germany
Prior art keywords
leptin
leptin antagonists
antagonists
amino acid
acid residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005026432T
Other languages
English (en)
Inventor
Arieh Gertler
Isabelle Callebaut
Jean Djiane
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Pierre et Marie Curie Paris 6
Institut National de la Recherche Agronomique INRA
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Universite Pierre et Marie Curie Paris 6
Institut National de la Recherche Agronomique INRA
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Pierre et Marie Curie Paris 6, Institut National de la Recherche Agronomique INRA, Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Universite Pierre et Marie Curie Paris 6
Publication of DE602005026432D1 publication Critical patent/DE602005026432D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE602005026432T 2004-11-26 2005-11-24 Leptin antagonisten Active DE602005026432D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/996,607 US7307142B2 (en) 2004-11-26 2004-11-26 Leptin antagonists
PCT/IL2005/001250 WO2006056987A2 (en) 2004-11-26 2005-11-24 Leptin antagonists

Publications (1)

Publication Number Publication Date
DE602005026432D1 true DE602005026432D1 (de) 2011-03-31

Family

ID=36204374

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005026432T Active DE602005026432D1 (de) 2004-11-26 2005-11-24 Leptin antagonisten

Country Status (8)

Country Link
US (1) US7307142B2 (de)
EP (1) EP1814986B1 (de)
JP (1) JP5113526B2 (de)
CN (1) CN101189335B (de)
AT (1) ATE498683T1 (de)
DE (1) DE602005026432D1 (de)
ES (1) ES2363011T3 (de)
WO (1) WO2006056987A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8716220B2 (en) * 2005-09-07 2014-05-06 Nikolaos Tezapsidis Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta
US8227408B2 (en) * 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
EP2326339A4 (de) * 2008-05-21 2012-06-20 Neurotez Inc Verfahren zur behandlung von progressiven kognitiven störungen im zusammenhang mit neurofibrillären tangles
US8778890B2 (en) 2009-03-31 2014-07-15 Temple University—Of the Commonwealth System of Higher Education Leptin antagonist and methods of use
MX2012012229A (es) 2010-04-22 2013-03-05 Yissum Res Dev Co Leptinas de alta afinidad y antagonistas de leptina.
WO2014024189A1 (en) * 2012-08-06 2014-02-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Pegylated high affinity leptins with increased biological activity
IT1423968B1 (de) * 2014-04-28 2016-08-26
US10926006B2 (en) 2015-02-26 2021-02-23 Remodeless Cv Ltd Drug eluting stent
US11123461B2 (en) 2015-02-26 2021-09-21 Remodeless Cv Ltd Treatment of ischemia and reperfusion using leptin antagonist
CA2977607A1 (en) 2015-02-26 2016-09-01 Jacob Schneiderman Methods and compositions relating to leptin antagonists
CN104829708B (zh) * 2015-05-06 2017-11-28 广东省生物资源应用研究所 一条d螺旋区突变的瘦素活性肽及其编码基因和应用
CN104829707B (zh) * 2015-05-06 2017-12-19 广东省生物资源应用研究所 一条cd环和e螺旋区突变的瘦素活性肽及其编码基因和应用
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
JP7042816B2 (ja) * 2016-11-08 2022-03-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッド レプチン受容体をアンタゴナイズする抗原結合性タンパク質
MX2021007394A (es) 2018-12-18 2021-07-15 Regeneron Pharma Composiciones y metodos para aumentar el peso corporal y la masa muscular magra mediante el uso de antagonistas contra el receptor de leptina, gdf8 y activina a.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
WO1997020933A2 (en) * 1995-12-06 1997-06-12 Schering Corporation MUTATIONAL VARIANTS OF MAMMALIAN Ob GENE PROTEINS
US20020160935A1 (en) * 2000-03-24 2002-10-31 Smithkline Beecham Plc Use of leptin antagonists for the treatment of diabetes
WO1998012224A1 (en) * 1996-09-20 1998-03-26 Hoechst Aktiengesellschaft Use of leptin antagonists for treating insulin resistance in type ii diabetes
HUP0402071A2 (hu) * 2001-02-06 2005-01-28 Merck Patent Gmbh. Csökkentett immunogenitású, módosított leptin

Also Published As

Publication number Publication date
ATE498683T1 (de) 2011-03-15
CN101189335A (zh) 2008-05-28
JP5113526B2 (ja) 2013-01-09
US20060154859A1 (en) 2006-07-13
WO2006056987A3 (en) 2006-08-24
EP1814986A2 (de) 2007-08-08
CN101189335B (zh) 2012-01-11
WO2006056987A2 (en) 2006-06-01
ES2363011T3 (es) 2011-07-18
US7307142B2 (en) 2007-12-11
JP2008521795A (ja) 2008-06-26
EP1814986B1 (de) 2011-02-16

Similar Documents

Publication Publication Date Title
ATE498683T1 (de) Leptin antagonisten
CY1117124T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ANTΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
IL187168A (en) Proteins or polypeptides containing two identical nanobedis against Factor von Willebrand, methods for their preparation, medicinal preparations containing them and their use
TW200745163A (en) Peptides that block the binding of IgG to FcRn
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
CY1113199T1 (el) Σταθεροποιημενες συνθεσεις γλυκοσερεμπροσιδασης
EA201792245A1 (ru) Биоконъюгаты и их применения
DK1615952T3 (da) Fremgangsmåder til behandling af betændelsestilstande med specifikke, til humant angiopoietin-2-bindende midler
NO20065217L (no) Polymerbasert forsinket frigjoringsutstyr
MA32982B1 (fr) Proteines de liaison au recepteur cgrp humain
DK2035447T3 (da) Polypeptid
ATE428727T1 (de) Neue, an den erythropoietinrezeptor bindende peptide
WO2006138343A3 (en) Compositions comprising receptor - associated protein (rap) variants specific for lrp2 and uses thereof
SMP200800060B (it) Anticorpi che legano la proteina umana tirosina fosfatasi beta (hptbeta) e loro usi
EA201071126A1 (ru) Антагонисты рецепторов глюкагона
ATE491349T1 (de) Neue nutrazeutika-zusammensetzungen
CY1110980T1 (el) Εμβολιο συνδυασμων πεπτιδιων εναντια στην αλλεργια απο γατες
EA201100072A1 (ru) Новые композиции и способы
DE602005025090D1 (de) Methoden zur steigerung der protein polyethylenglykol (peg) konjugation
EA201100071A1 (ru) Новые композиции и способы
MX2008000230A (es) Proteinas de enlace il-6.
WO2006125201A3 (en) Anti-biotin-pegylated-mcp-1 mutein antibodies, compositions, methods and uses
ATE514714T1 (de) Hutnfr1-selektive antagonisten
ATE543833T1 (de) Bmp-7-varianten-zusammensetzungen, verfahren und verwendungen
WO2008086035A3 (en) Split mutant hydrolase fusion reporter and uses thereof